Halozyme Therapeutics Inc. (NASDAQ: HALO) will need some therapeutics of its own, as are its shareholders. Its shares got pounded Friday morning on news of a temporary halt of its Phase II trial enrollment and dosing for its pancreatic cancer study. Halozyme reported Friday morning that the company will temporarily halt patient enrollment and dosing of PEGPH20 in its ongoing Phase II trial evaluating PEGPH20 in patients with pancreatic cancer. This decision to halt the enrollment was based on a recommendation received on Thursday from an independent Data Monitoring Committee.
Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $8.30 moved to $8.70 on last trade day and at the end of the day closed at $8.29. Company price to sales ratio in past twelve months was calculated as 18.76 and price to cash ratio as 14.38. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -32.66%.
In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on Prana Biotechnology Limited (NASDAQ: PRAN) from Buy to Hold, and lowered the price target from $11.00 to $3.00.Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares advanced 1.83% in last trading session and ended the day on $2.23. PRAN return on equity ratio is recorded as -143.90% and its return on assets is 3.00%. {Full Company Name} yearly performance is -114.00%.
PharmAthene, Inc. (AMEX: PIP) announced that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax® program.PharmAthene, Inc. (NYSEMKT:PIP) shares moved down -3.05% in last trading session and was closed at $1.59, while trading in range of $1.50-$1.62. PharmAthene, Inc. (NYSEMKT:PIP) year to date performance is -14.52%.
Ignyta Inc (NASDAQ:RXDX), an oncology precision medicine biotechnology company, announced that it has issued inducement awards to three new non-executive employees.The awards were made on March 31, 2014 under Ignyta’s Employment Inducement Incentive Award Plan, which was adopted March 28, 2014 and provides for the granting of equity awards to new employees of Ignyta. The inducement awards consist of options to purchase an aggregate of 135,000 shares of Ignyta common stock. The options have a ten-year term and an exercise price equal to $8.30, the fair market value of Ignyta common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of the date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by Ignyta’s board of directors and were granted as an inducement material to the new employees entering into employment with Ignyta in accordance with Nasdaq Marketplace Rule 5635(c)(4).Ignyta Inc (NASDAQ:RXDX) weekly performance is -22.24%. On last trading day company shares ended up $6.68. Ignyta Inc (NASDAQ:RXDX) distance from 50-day simple moving average is -41.93%. Analysts mean target price for the company is $20.00.
Leave a Reply